EP0970055A2 - Inhibiteurs de la protease du vih - Google Patents

Inhibiteurs de la protease du vih

Info

Publication number
EP0970055A2
EP0970055A2 EP98910300A EP98910300A EP0970055A2 EP 0970055 A2 EP0970055 A2 EP 0970055A2 EP 98910300 A EP98910300 A EP 98910300A EP 98910300 A EP98910300 A EP 98910300A EP 0970055 A2 EP0970055 A2 EP 0970055A2
Authority
EP
European Patent Office
Prior art keywords
compound
group
alkyl
purity
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98910300A
Other languages
German (de)
English (en)
Inventor
Kim F. Albizati
Siegfried Reich
Michael D. Varney
Kanyin E. Zhang
Takuo Kobayashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Agouron Pharmaceuticals LLC
Original Assignee
Japan Tobacco Inc
Agouron Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc, Agouron Pharmaceuticals LLC filed Critical Japan Tobacco Inc
Publication of EP0970055A2 publication Critical patent/EP0970055A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention relates to a novel series of chemical compounds useful as HIV protease inhibitors and to the use of such compounds as antiviral agents.
  • AIDS Acquired Immune Deficiency Syndrome
  • AIDS causes a gradual breakdown of the body's immune system as well as progressive deterioration of the central and peripheral nervous systems. Since its initial recognition in the early 1980 ' s, AIDS has spread rapidly and has now reached epidemic proportions within a relatively limited segment of the population.
  • HTLV-III human T-lymphotropic retrovirus III
  • HIV is a member of the class of viruses known as retroviruses .
  • the retroviral genome is composed of RNA which is converted to DNA by reverse transcription.
  • This retroviral DNA is then stably integrated into a host cell's chromosome and, employing the replicative processes of the host cells, produces new retroviral particles and advances the infection to other cells.
  • HIV appears to have a particular affinity for the human T-4 lymphocyte cell which plays a vital role in the body's immune system. HIV infection of these white blood cells depletes this white cell population.
  • the immune system is rendered inoperative and ineffective against various opportunistic diseases such as, among others, pneumocystic carini pneumonia, Kaposi ' s sarcoma, and cancer of the lymph system.
  • the drug azidothymidine has been found effective for inhibiting the reverse transcription of the retroviral genome of the HIV virus, thus giving a measure of control, though not a cure, for patients afflicted with AIDS.
  • the search continues for drugs that can cure or at least provide an improved measure of control of the deadly HIV virus .
  • Retroviral replication routinely features post- translational processing of polyproteins . This processing is accomplished by virally encoded HIV protease enzyme. This yields mature polypeptides that will subsequently aid in the formation and function of infectious virus. If this molecular processing is stifled, then the normal production of HIV is terminated. Therefore, inhibitors of HIV protease may function as anti-HIV viral agents.
  • HIV protease is one of the translated products from the HIV structural protein pol gene. This retroviral protease specifically cleaves other structural polypeptides at discrete sites to release these newly activated structural proteins and enzymes, thereby rendering the virion replication-competent. As such, inhibition of the HIV protease by potent compounds may prevent proviral integration of infected T-lymphocytes during the early phase of the HIV-1 life cycle, as well as inhibit viral proteolytic processing during its late stage. Additionally, the protease inhibitors may have the advantages of being more readily available, longer lived in virus, and less toxic than currently available drugs, possibly due to their specificity for the retroviral protease.
  • a novel class of chemical compounds that can inhibit and/or block the activity of the HIV protease, which halts the proliferation of HIV virus, pharmaceutical compositions containing these compounds, and the use of the compounds as inhibitors of the HIV protease.
  • the present invention relates to compounds falling within formula (9) below, and pharmaceutically acceptable salts, prodrugs, and solvates thereof, that inhibit the protease encoded by human immunodeficiency virus (HIV) type 1 (HIV-1) or type 2 (HIV-2) .
  • HIV human immunodeficiency virus
  • the compounds, their pharmaceutically acceptable salts, and the pharmaceutical compositions of the present invention can be used alone or in combination with other antivirals, immunomodulators, antibiotics or vaccines.
  • Compounds of the present invention can also be used as prodrugs . Methods of treating AIDS, methods of treating HIV infection and methods of inhibiting HIV protease are disclosed.
  • the compounds of the present invention are of the formula (9) :
  • R and R' are independently selected from H, a substituted or unsubstituted alkyl-ORi group, a cycloalkyl group substituted with a (Ci-Cg) alkyl group or a (Ci- Cg) alkyl-OH group, a heterocycle group substituted with a (Ci-Cg) alkyl group or a (C ⁇ -C 6 ) alkyl-OH group, an alkyl-NR 2 R 3 group, or an alkyl -S (X) (Y) R 4 group, wherein
  • Ri is H, a substituted or unsubstituted alkyl group, or an acyl group
  • R 2 and R 3 are each independently selected from H, substituted or unsubstituted alkyl, cycloalkyl, heterocycle, and aryl groups, and acyl and sulfonyl groups ;
  • R 4 is H, a substituted or unsubstituted alkyl, cycloalkyl, heterocycle, or aryl group;
  • R is H. More preferably, R is H and R' is a cycloalkyl group selected from:
  • Ri is H.
  • the alkyl-ORi is selected from -C (CH 3 ) 2 CH 2 OH, -CH (CH 3 ) CH 2 OH, ⁇ CH 2 CH 2 0H, -C(CH 3 ) (CH 2 OH) 2 , -C (CH 3 ) 2 -0-CH 2 -0-CH 3 , -C (CH 3 ) 2 CH 2 -0- CH 2 -0-CH 3 , and -C (CH 3 ) 2 CH 2 -0-acyl , or a pharmaceutically acceptable prodrug, salt or solvate thereof.
  • R and R 1 is a cycloalkyl group substituted with a (Ci-C 6 ) alkyl group or a (Ci-Cg) alkyl-OH group
  • the cycloalkyl group is selected from:
  • the heterocycle group is selected from:
  • R 3 is H, a substituted or unsubstituted alkyl, cycloalkyl, heterocycle, or aryl group, or an acyl or sulfonyl group.
  • a preferred species of the formula (9) is [3S- [2 (2S*,3S*) ,3 alpha, 4a beta, 8a beta] ] -N- (1 , 1 -dimethyl -2 ⁇ hydroxyethyl ) decahydro-2- [2 -hydroxy-3- [ (3-hydroxy-2- methylbenzoyl) amino] -4- (phenylthio) butyl] -3- isoquinolinecarboxamide
  • Preferred prodrugs can be obtained by replacing the hydrogen in one of the alcohol groups with an acyl group, and more preferably an amino acid acyl group.
  • the present invention further provides pharmaceutical formulations comprising an effective amount of a compound of formula (9) or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier, such as a diluent or excipient .
  • the present invention further provides a method of treating AIDS comprising administering to a host or patient, such as a primate, an effective amount of a compound of the present invention.
  • the present invention further provides a method of inhibiting HIV replication comprising administering to an HIV infected cell, a cell susceptible to HIV infection or a host or patient, such as a primate, an effective amount of a compound of the present invention.
  • the present invention provides new compounds falling within formula (9) , as described above, that are useful for treating HIV infection and/or AIDS.
  • Compounds of the formula (9) may be prodrugs, which can serve to improve the pharmaceutical properties of the compounds, such as pharmacokinetic properties, for example, improved bioavailability or solubility.
  • the preparation of prodrugs may be carried out by standard methods known to those skilled in the art.
  • a preferred prodrug can be obtained by acylation or alkylation of the starting alcohol when R or R 1 is CH (CH 3 ) 2 CH 2 0H.
  • alkyl refers to straight or branched chain groups, preferably, having one to eight, more preferably having one to six, and most preferably having from one to four carbon atoms.
  • the term "Ci-C 6 alkyl” represents a straight or branched alkyl chain having from . one to six carbon atoms.
  • Exemplary Ci-C 6 alkyl groups include methyl, ethyl, n- propyl , isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl , neo-pentyl, hexyl , isohexyl, and the like.
  • the term "Ci-C 6 alkyl” includes within its definition the term "Ci-C 4 alkyl".
  • cycloalkyl represents a saturated or partially saturated, mono- or poly-carbocylic ring, preferably having 5-14 ring carbon atoms.
  • exemplary cycloalkyls include monocyclic rings having from 3-7, preferably 3-6, carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
  • An exemplary cycloalkyl is a C 5 -C 7 cycloalkyl, which is a saturated hydrocarbon ring structure containing from five to seven carbon atoms.
  • alkoxyl represents -0-alkyl.
  • An example of an alkoxyl is a Cj-Cg alkoxyl, which represents a straight or branched alkyl chain having from one to six carbon atoms attached to an oxygen atom.
  • Exemplary Ci-C 6 alkoxyl groups include methoxyl, ethoxyl, propoxyl, isopropoxyl, butoxyl, sec-butoxyl, t -butoxyl, pentoxyl , hexoxyl , and the like.
  • Ci-C 6 alkoxyl includes within its definition a Ci-C 4 alkoxyl.
  • aryl refers to a carbocyclic or heterocyclic, aromatic, 5-14 membered monocyclic or polycyclic ring.
  • exemplary aryls include phenyl , naphthyl , anthryl , phenanthryl , thienyl, pyrrolyl , imidazolyl, pyrazolyl, furyl , isothiazolyl , furazanyl, isoxazolyl, thiazolyl, pyridyl , pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, benzo [b] thienyl , naphtho [2 , 3-b] thianthrenyl , isobenzofuranyl , chromenyl , xanthenyl , phenoxathienyl , indolizinyl, isoindolyl, indolyl , indolyl
  • hydrolyzable group is a group, which when bonded to an oxygen, forms an ester, which can be hydrolyzed in vivo to a hydroxyl group.
  • exemplary hydrolyzable groups which are optionally substituted, include acyl function, sulfonate function and phosphate function.
  • such hydrolyzable groups include blocked or unblocked amino acid residue, a hemisuccinate residue, and a nicotinate residue .
  • halogen represents chlorine, fluorine, bromine or iodine.
  • halo represents chloro, fluoro, bromo or iodo.
  • carrier represents an aromatic or a saturated or a partially saturated 5-14 membered monocyclic or polycyclic ring, such as a 5- to 7-membered monocyclic or 7- to 10-membered bicyclic ring, wherein all the ring members are carbon atoms .
  • heterocycle represents an aromatic or a saturated or a partially saturated, 5-14 membered, monocylic or polycyclic ring, such as a 5- to 7-membered monocyclic or 7- to 10-membered bicyclic ring, having from one to three heteroatoms selected from nitrogen, oxygen and sulfur, and wherein any nitrogen and sulfur heteroatoms may optionally be oxidized, and any nitrogen heteroatom may optionally be quaternized.
  • the heterocyclic ring may be attached at any suitable heteroatom or carbon atom.
  • heterocycles include decahydroisoquinolinyl , octahydro-thieno [3 , 2-c] pyridinyl , piperidinyl, piperazinyl, azepinyl, pyrrolyl , pyrrolidinyl , pyrazolyl, pyrazolidinyl , imidazolyl, isobenzofuranyl , furazanyl , imidazolinyl , imidazolidinyl , pyridyl , pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl , isoxazolyl, thianthrenyl , triazinyl, isoxazolidinyl, morpholinyl, thiazolyl, thiazolidinyl , isothiazolyl, quinuclidinyl , iso-
  • thioether includes S-aryl, such as phenylthio and naphthylthio; S-heterocycle where the heterocycle is saturated or partially saturated; S- (C 5 -C 7 ) -cycloalkyl ; and S-alkyl, such as Ci-C 6 alkylthio.
  • the -aryl, the -heterocycle, the -cycloalkyl and the -alkyl can optionally be substituted.
  • An example of a thioether is "C ⁇ -C 6 alkylthio", which represents a straight or branched alkyl chain having from one to six carbon atoms attached to a sulfur atom.
  • Ci-C 6 alkylthio groups include methylthio, ethylthio, propylthio, isopropylthio, butylthio, sec- butylthio, t-butylthio, pentylthio, hexylthio, and the like.
  • mercapto represents -SH.
  • amino represents -NL ⁇ 2 , wherein Li and L 2 are preferably independently selected from oxygen, carbocycle, heterocycle, alkyl, sulfonyl and hydrogen; or NC(0)L 3 , wherein L 3 is preferably alkyl, alkoxyl, hydrogen or -NL ⁇ L 2 .
  • the aryl, alkyl and alkoxyl groups can optionally be substituted.
  • An example of an amino is Ci ⁇ C 4 alkylamino, which represents a straight or branched alkyl chain having from one to four carbon atoms attached to an amino group.
  • Ci-C 4 alkylamino groups include methylamino, ethylamino, propylamino, isopropylamino, butylamino, sec- butylamino, and the like.
  • Another example of an amino is di (C ⁇ -C 4 ) alkylamino, which represents two straight or branched alkyl chains, each having from one to four carbon atoms attached to a common amino group.
  • Exemplary di (C 1 - C 4 ) alkylamino groups include dimethylamino, ethylmethylamino, methylpropylamino, ethylisopropylamino, butylmethylamino, sec-butylethylamino, and the like.
  • An example of an amino is C ⁇ -C 4 alkylsulfonylamino, which has a straight or branched alkyl chain having from one to four carbon atoms attached to a sulfonylamino moiety.
  • Exemplary C ⁇ -C 4 alkylsulfonylamino groups include methylsulfonylamino, ethylsulfonylamino, propylsulfonylamino, isopropylsulfonylamino, butylsulfonylamino, sec- butylsulfonylamino, t-butylsulfonylamino, and the like.
  • acyl represents L 6 C(0)L 4 , wherein L 6 is a single bond, -O or -N, and further wherein L 4 is preferably alkyl, amino, hydroxyl , alkoxyl or hydrogen.
  • the alkyl and alkoxyl groups can optionally be substituted.
  • An exemplary acyl is a Ci-C alkoxycarbonyl , which is a straight or branched alkoxyl chain having from one to four carbon atoms attached to a carbonyl moiety.
  • Exemplary Ci ⁇ C 4 alkoxycarbonyl groups include methoxycarbonyl , ethoxycarbonyl , propoxycarbonyl , isopropoxycarbonyl, butoxycarbonyl , and the like.
  • acyl is a carboxy wherein L 6 is a single bond and L 4 is alkoxyl, hydrogen, or hydroxyl.
  • a further exemplary acyl is N- (Ci- C 4 ) alkylcarbamoyl (L 6 is a single bond and L 4 is an amino), which is a straight or branched alkyl chain having from one to four carbon atoms attached to the nitrogen atom of a carbamoyl moiety.
  • Exemplary N- (Ci-C 4 ) alkylcarbamoyl groups include N-methylcarbamoyl , N-ethylcarbamoyl ,
  • Yet another exemplary acyl is N, N-di (Ci ⁇ C 4 ) alkylcarbamoyl, which has two straight or branched alkyl chains, each having from one to four carbon atoms attached to the nitrogen atom of a carbamoyl moiety.
  • N, N-di (C ⁇ -C 4 ) alkylcarbamoyl groups include N,N-dimethylcarbamoyl, N,N-ethylmethylcarbamoyl , N,N- methylpropylcarbamoyl, N,N-ethylisopropylcarbamoyl , N,N- butylmethylcarbamoyl , N,N-sec-butylethylcarbamoyl , and the like.
  • sulfinyl represents -S0-L 5 , wherein L 5 is preferably alkyl, amino, aryl, cycloalkyl or heterocycle.
  • L 5 is preferably alkyl, amino, aryl, cycloalkyl or heterocycle.
  • the alkyl, aryl, cycloalkyl and heterocycle can all optionally be substituted.
  • sulfonyl represents -S0 2 -L 5 , wherein L 5 is preferably alkyl, aryl, cycloalkyl, heterocycle or amino.
  • L 5 is preferably alkyl, aryl, cycloalkyl, heterocycle or amino.
  • the alkyl, aryl, cycloalkyl and heterocycle can all optionally be substituted.
  • An example of a sulfonyl is a C ⁇ -C 4 alkylsulfonyl, which is a straight or branched alkyl chain having from one to four carbon atoms attached to a sulfonyl moiety.
  • Exemplary C ⁇ -C 4 alkylsulfonyl groups include methylsulfonyl , ethylsulfonyl , propylsulfonyl , isopropylsulfonyl, butylsulfonyl , sec-butylsulfonyl , t- butylsulfonyl and the like.
  • alkyl As indicated above, many of the groups are optionally substituted. In fact, unless specifically noted, all of the groups defined by the terms defined in this application may be substituted or unsubstituted. For instance, when the term "alkyl” is used, it should be understood to encompass both substituted and unsubstituted alkyl unless specific exclusion of one or the other is positively stated.
  • substituents for alkyl and aryl include mercapto, thioether, nitro (N0 2 ) , amino, aryloxyl, halogen, hydroxyl, alkoxyl, and acyl, as well as aryl, cycloalkyl and saturated and partially saturated heterocycles .
  • substituents for heterocycle and cycloalkyl include those listed above for alkyl and aryl, as well as aryl and alkyl.
  • Exemplary substituted aryls include a phenyl or naphthyl ring substituted with one or more substituents, preferably one to three substituents, independently selected from halo, hydroxy, morpholino (C ⁇ -C 4 ) alkoxy carbonyl, pyridyl (C 1 -C 4 ) alkoxycarbonyl, halo (C ⁇ C 4 ) alkyl , C ⁇ -C 4 alkyl, C x -C 4 alkoxy, carboxy, C ⁇ -C 4 alkoxycarbonyl, carbamoyl, N- (Ci-C 4 ) alkylcarbamoyl , amino, Ci ⁇ C 4 alkylamino, di (Ci-C 4 ) alkylamino or a group of the formula -(CH 2 ) a -R 7 where a is 1, 2, 3 or 4; and R 7 is hydroxy, C ⁇ -C 4 alkoxy, carboxy, Ci-C 4 alkoxy
  • halo (Ci-C 4 ) alkyl which represents a straight or branched alkyl chain having from one to four carbon atoms with 1-3 halogen atoms attached to it.
  • exemplary halo (C ⁇ C 4 ) alkyl groups include chloromethyl , 2- bromoethyl, 1-chloroisopropyl , 3-fluoropropyl , 2 , 3-dibromobutyl, 3 -chloroisobutyl , iodo-t-butyl , trifluoromethyl and the like.
  • hydroxy (C ⁇ -C 4 ) alkyl which represents a straight or branched alkyl chain having from one to four carbon atoms with a hydroxy group attached to it.
  • exemplary hydroxy (Ci-C 4 ) alkyl groups include hydroxymethyl , 2 -hydroxyethyl , 3 -hydroxypropyl , 2 -hydroxy- isopropyl, 4-hydroxybutyl and the like.
  • Ci-C 4 alkylthio (C,- C 4 ) alkyl which is a straight or branched Ci ⁇ C 4 alkyl group with a Ci-C 4 alkylthio group attached to it.
  • Exemplary Ci-C 4 alkylthio (Ci-C 4 ) alkyl groups include methylthiomethyl , ethylthiomethyl, propylthiopropyl, sec-butylthiomethyl, and the like.
  • heterocycle (Ci- C 4 ) alkyl which is a straight or branched alkyl chain having from one to four carbon atoms with a heterocycle attached to it .
  • exemplary heterocycle (Cj-C 4 ) alkyls include pyrrolylmethyl , quinolinyl- methyl, 1-indolylethyl, 2-furylethyl, 3-thien-2-ylpropyl , 1- imidazolylisopropyl, 4-thiazolylbutyl and the like.
  • aryl (C ⁇ -C 4 ) alkyl which is a straight or branched alkyl chain having from one to four carbon atoms with an aryl group attached to it .
  • exemplary aryl (Ci-C 4 ) alkyl groups include phenylmethyl , 2-phenylethyl, 3-naphthyl-propyl , 1-naphthylisopropyl , 4-phenylbutyl and the like.
  • the heterocycle can, for example, be substituted with 1, 2 or 3 substituents independently selected from halo, halo(C ⁇ - C 4 ) alkyl, C ⁇ -C 4 alkyl, C ⁇ C 4 alkoxy, carboxy, C x -C 4 alkoxycarbonyl, carbamoyl, N- (C ⁇ -C 4 ) alkylcarbamoyl , amino, Ci-C 4 alkylamino, di (Ci-C ) alkylamino or a group having the structure -(CH 2 ) a -R 7 where a is 1, 2, 3 or 4 and R 7 is hydroxy, Ci-C 4 alkoxy, carboxy, C ⁇ -C 4 alkoxycarbonyl , amino, carbamoyl, Ci-C 4 alkylamino or di (Cj-C 4 ) alkylamino .
  • substituents independently selected from halo, halo(C ⁇ - C 4 ) alkyl, C ⁇
  • substituted heterocycles include 3-N-t-butyl carboxamide decahydroisoquinolinyl, 6-N-t-butyl carboxamide octahydro-thieno [3 , 2-c] pyridinyl , 3 -methylimidazolyl , 3-methoxypyridyl , 4-chloroquinolinyl , 4-aminothiazolyl, 8-methylquinolinyl, 6-chloroquinoxalinyl , 3-ethylpyridyl , 6-methoxybenzimidazolyl , 4-hydroxyfuryl, 4-methylisoquinolinyl , 6 , 8-dibromoquinolinyl , 2 -methyl - 1,2,3, 4-tetrahydroisoquinolinyl, N-methyl-quinolin-2-yl , 2-t-butoxycarbonyl-l, 2 , 3 , 4-isoquinolin-7-yl and the like
  • Exemplary heterocyclic ring systems represented by A or B include (1) 5 -membered monocyclic ring groups such as thienyl, pyrrolyl , imidazolyl, pyrazolyl, furyl , isothiazolyl, furazanyl , isoxazolyl, thiazolyl and the like; (2) 6-membered monocyclic groups such as pyridyl, pyrazinyl, pyrimidinyl, pyridazinly, triazinyl and the like; and (3) polycyclic heterocyclic rings groups, such as decahydroisoquinolinyl, octahydro-thieno [3, 2-c] pyridinyl, benzo [b] thienyl , naphtho [2,3 -b] thianthrenyl , isobenzofuranyl , chromenyl , xanthenyl , and fully or partially saturated analogs thereof.
  • a cycloalkyl may be optionally substituted with 1 , 2 or 3 substituents independently selected from halo, halo (C x -C 4 ) alkyl, C ⁇ -C 4 alkyl, C ⁇ -C 4 alkoxy, carboxy, C ⁇ -C 4 alkoxycarbonyl, carbamoyl, N- (C x -C 4 ) alkylcarbamoyl , amino, Ci-Cj alkylamino, di (Ci-C ) alkylamino or a group having the structure - (CH 2 ) a -R 7 where a is 1, 2, 3 or 4 and R 7 is hydroxy, Ci-C 4 alkoxy, carboxy, Ci-C 4 alkoxycarbonyl, amino, carbamoyl, Ci-C 4 alkylamino or di (Ci-C 4 ) alkylamino .
  • Exemplary substituted cycloalkyl groups include 3 -methylcyclopentyl , 4-eth
  • Exemplary substituted hydrolyzable groups include N-benzyl glycyl , N-Cbz- -valyl , and N-methyl nicotinate.
  • the compounds of the present invention have at least five asymmetric centers denoted by an asterisk in the formula (9) below:
  • the compounds of the present invention can occur in any of the possible stereoisomeric forms, and can be used in mixtures of stereoisomers, which can be optically active or racemic, or can be used alone as essentially pure stereisomers, i.e., at least 95% pure. All asymmetric forms, individual stereoisomers and combinations thereof, are within the scope of the present invention.
  • the individual stereoisomers may be prepared from their respective precursors by the procedures described above, by resolving the racemic mixtures, or by separating the diastereomers .
  • the resolution can be carried out in the presence of a resolving agent , by chromatography or by repeated crystallization or by some combination of these techniques which are known in the art. Further details regarding resolutions can be found in Jacques et al . , Enantiomers, Racemates, and Resolutions, John Wiley & Sons 1981.
  • the compounds of the present invention are substantially pure, i.e, over 50% pure. More preferably, the compounds are at least 75% pure. Even more preferably, the compounds are more than 90% pure. Even more preferably, the compounds are at least 95% pure, more preferably, at least 97% pure, and most preferably at least 99% pure.
  • the invention includes the pharmaceutically acceptable salts of the compounds defined by formula (9) .
  • a compound of this invention may possess a sufficiently acidic, a sufficiently basic, or both functional groups, and accordingly react with any of a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.
  • pharmaceutically acceptable salt refers to salts of the compounds of the above formula which are substantially non-toxic to living organisms.
  • Exemplary pharmaceutically acceptable salts include those salts prepared by reaction of the compounds of the present invention with a mineral or organic acid or an inorganic base.
  • the reactants are generally combined in a mutual solvent such as diethylether or benzene, for acid addition salts, or water or alcohols for base addition salts.
  • a mutual solvent such as diethylether or benzene
  • the salts normally precipitate out of solution within about one hour to about ten days and can be isolated by filtration or other conventional methods. Such salts are known as acid addition and base addition salts.
  • Acids that may be employed to form acid addition salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids such as p-toluenesulfonic, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like
  • organic acids such as p-toluenesulfonic, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like.
  • Examples of pharmaceutically acceptable salts are the sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1, 4-dioate, hexyne-1 , 6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbut
  • Preferred pharmaceutically acceptable acid addition salts are those formed with mineral acids such as hydrochloric acid and hydrobromic acid, and those formed with organic acids such as maleic acid and methanesulfonic acid.
  • Base addition salts include those derived from inorganic and organic bases, such as ammonium or alkali or alkaline earth metal hydroxides, carbonates, bicarbonates, and the like.
  • bases useful in preparing the salts of this invention thus include sodium hydroxide, potassium hydroxide, ammonium hydroxide, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate, calcium hydroxide, calcium carbonate and the like.
  • the potassium and sodium salt forms are particularly preferred.
  • a "pharmaceutically acceptable prodrug” is intended to mean a compound that may be converted under physiological conditions or by solvolysis to a compound of the formula 9.
  • a “pharmaceutically acceptable solvate” is intended to mean a solvate that retains the biological effectiveness and properties of the biologically active components of compounds of formula 9.
  • Examples of pharmaceutically acceptable solvates include, but are not limited to, compounds of formula 9 in combination with water, isopropanol, ethanol, methanol , DMSO, ethyl acetate, acetic acid, or ethanolamine .
  • any salt of this invention is not of a critical nature, so long as the salt as a whole is pharmacologically acceptable and as long as the counterion does not contribute undesired qualities to the salt as a whole.
  • a preferred compound is compound 21
  • Compound 21 has also been obtained as a metabolite from the plasma of patients administered [3S-
  • the compounds of formula 9 can be prepared according to the following Reaction Scheme I.
  • Compound la perhydroisoquinoline, which is commercially available from NSC Technologies (Chicago, IL) or Procos SpA (Milan, Italy) is subjected to prolonged acid hydrolysis in step la to obtain compound 2a.
  • a variety of inorganic acids may be used in either an aqueous/organic solvent mixture or in water alone at temperatures above 50 °C.
  • An example of such an inorganic acid is 6N aqueous HC1.
  • Substitutes for compound la include the corresponding esters lb, thioesters lc or other amides Id:
  • Z, Z x and Z 2 may each independently be alkyl, cycloalkyl, heterocycle, or aryl.
  • Compound 2a is then protected at the amine nitrogen to obtain compound 2b in step lb .
  • the protecting group R p is defined as a suitably conjugating group to avoid unwanted decomposition of activated carboxylate derivatives of compound 2b in Step 2 .
  • Such protecting groups typically can be carbamate in origin, having a general structure of formula 11:
  • R" in formula 11 can be any alkyl, cycloalkyl, aryl, or heterocycle which can be removed easily in a deprotection step after Step 2 .
  • R" include, but are not limited to methyl, ethyl, propyl , isopropyl, n-butyl, isobutyl, t-butyl or higher branched or unbranched alkyl, 2 , 2 , 2-trichloroethyl , 2- trimethylsilylethyl, allyl, phenyl , substituted phenyl , benzyl, substituted benzyl, 9-fluorenylmethyl , 9- anthrylmethyl and higher polycyclic aromatic ring system.
  • the following materials, as defined below, can be obtained from the Aldrich Chemical Co. (Sigma Aldrich Fluka) : ⁇
  • a suitable base in typical organic solvents for these types of reactions such as halogenated solvents, ethers and hydrocarbons.
  • bases are typically inorganic, such as metal hydroxides, bicarbonates and carbonates or organic bases such as amines like triethylamine, diethylamine, diethyl isopropylamine, 1,8- diazabicyclo [2.2.2] octane (DABCO) or related di- or trialkyl -amines, as well as amidine bases like 1,8- diazabicyclo [5.4.0] undec-7-ene (DBU) and 1,8- diazabicyclo [4.3.0] non-5-ene (DBN) .
  • DBU 1,8- diazabicyclo [5.4.0] undec-7-ene
  • DBN 1,8- diazabicyclo [4.3.0] non-5-ene
  • the amide coupling Step 2 can be accomplished in any number of fashions depending on how the carboxyl group is activated.
  • a group J is installed in Step 2 by reaction of the carboxylic acid 2b to produce the activated derivative
  • the group J can be any of a variety of leaving groups such as alkoxy, hydroxy, halogen, pseudohalogen (including azide, cyanide, isocyanate and isothiocyanate), alkyl or arenesulfonate, aromatic heterocycle (bonded through a heteroatom) and N-hydroxyheterocycle, including hydroxysuccinimide or hydroxybenzotriazole ester.
  • leaving groups such as alkoxy, hydroxy, halogen, pseudohalogen (including azide, cyanide, isocyanate and isothiocyanate), alkyl or arenesulfonate, aromatic heterocycle (bonded through a heteroatom) and N-hydroxyheterocycle, including hydroxysuccinimide or hydroxybenzotriazole ester.
  • Esters (2c, J OR)
  • R is defined above
  • R may be prepared in a variety of ways starting from the acid chloride 2c where J is Cl by combination with the desired alcohol in the presence of an organic or inorganic base stated previously for the acylation of compound 12a or compound 12b.
  • the ester may be produced by acid-promoted esterification in the presence of the desired alcohol.
  • OSOj. i where Vl 1 is alkyl or aryl
  • Vl 1 is alkyl or aryl
  • alkyl or arylsulfonyl chlorides in the presence of an organic amine base such as triethylamine in a non-polar solvent at temperatures below 0 °C.
  • bases include, but are not limited to metal hydroxides, bicarbonates and carbonates or organic bases such as amines like triethylamine, diethylamine, diethyl isopropylamine, 1 , 8-diazabicyclo [2.2.2] octane (DABCO) or related di- or trialkylamines, as well as amidine bases like 1, 8-diazabicyclo [5.4.0] undec-7-ene (DBU) and 1,8- diazabicyclo [4.3.0] non-5-ene (DBN) .
  • a particularly preferred base is triethylamine.
  • the heteroaromatic derivatives of 2c are also made from the acid halides 2c (J)
  • the primary or secondary amine (shown above the arrow in Step 2 of Scheme I) used in the coupling process may incorporate suitable protecting groups, depending on the functionality present in the amine and the mode of coupling used.
  • the mode of coupling of 2c with a primary or secondary amine can be carried out in a variety of ways depending on the identity of J.
  • the coupling can be performed using carbodiimide-based methods utilizing any of the common reagents of this class, including dicyclohexylcarbodiimide or related dialkylcarbodiimides, EDC (salts of l-(3- dimethylaminopropyl) -3-ethylcarbodiimide) or related water- soluble reagents along with an organic amine base in polar organic solvents such as dioxane, DMF, NMP and acetonitrile in the presence of an N-hydroxyheterocyclic compound such as N-hydroxysuccinimide or 3 -hydroxybenzotriazole .
  • haloformate esters such as 12d, may be used to temporarily activate the acid to give mixed anhydrides of general formula 2d.
  • Such haloformate esters are typically as shown in 12d above and include methyl-, ethyl-, isopropyl-, isobutyl-, n-butyl, phenyl- and related alkyl and aryl chloroformates, defined below.
  • Formula 2d is a possible intermediate in the step from formula 2b to formula 3.
  • Formula 2d is an intermediate, but the process described here results in formula 3, without isolation of Formula 2d.
  • the coupling can be performed in a variety of non-polar organic solvents like halocarbons and ethers, such as diethyl ether, methyl t-butylether, diisopropyl ether, dioxane and THF at temperatures below 0 °C, accompanied by an organic amine base such as triethylamine, diethylamine, diethyl isopropylamine, DABCO or related di- or trialkylamines, as well as amidine bases like DBU and DBN.
  • non-polar organic solvents like halocarbons and ethers, such as diethyl ether, methyl t-butylether, diisopropyl ether, dioxane and THF at temperatures below 0 °C, accompanied by an organic amine base such as triethylamine, diethylamine, diethyl isopropylamine, DABCO or related di- or trialkylamines, as well as amidine bases like D
  • the coupling may be performed in most common organic solvents such as THF, diethyl ether, dioxane, methyl t-butyl ether or other ethers; acetone, cyclohexanone, methyl isobutylketone and other ketones; esters such as ethyl, methyl and isopropyl acetate; halogenated solvents such as halogenated methanes and ethanes, chlorobenzene and other halogenated benzenes; nitriles such acetonitrile and propionitrile; lower alcohols such as ethanol, isopropanol, t-butanol and related alcohols; and polar organic solvents such as dimethylformamide, dimethylsulfoxide, N-methyl-2- pyrrollidone and related amide-containing solvents.
  • organic solvents such as THF, diethyl ether, dioxane, methyl t-butyl ether or other
  • a base is frequently used and may be any of a number of inorganic bases such as metal hydroxides, bicarbonates and carbonates or organic bases such as amines like triethylamine, diethylamine, diethyl isopropylamine, DABCO or related di- or trialkylamines, as well as amidine bases like DBU and DBN.
  • inorganic bases such as metal hydroxides, bicarbonates and carbonates or organic bases such as amines like triethylamine, diethylamine, diethyl isopropylamine, DABCO or related di- or trialkylamines, as well as amidine bases like DBU and DBN.
  • protecting group removal can be accomplished using any of the standard methods for deprotecting a particular class of protecting group.
  • Simple alkyl- and substituted alkyl carbamates can be removed with aqueous solutions of base at temperatures up to about 100 °C, employing any of the common inorganic metal hydroxides such as sodium-, lithium-, potassium- or barium hydroxide or hydroxides of other metals in at least stoichiometric amounts.
  • Carbamate protecting groups that contain benzyl groups bonded to oxygen may be removed by hydrogenolysis with a palladium or platinum catalyst.
  • aqueous base hydrolysis may be used at temperatures up to about 100 °C, employing any of the common inorganic metal hydroxides such as sodium-, lithium-, potassium- or barium hydroxide or hydroxides of other metals in at least stoichiometric amounts.
  • a variety of anhydrous acids may also be used for deprotection of benzyl-based carbamates, including HCl, HBr and HI.
  • Lewis acids of boron and aluminum such as A1C1 3 , BBr 3 , BC1 3 in non-polar solvents are also effective.
  • Certain substituted benzyl, aryl or alkyl groups in which the specific substitution pattern is chosen for its ability to be removed under specific conditions may also be used.
  • the 2- trimethylsilylethylcarbonyl group (Teoc) is a protecting group designed to take advantage of the specific reactivity of the 2-trimethylsilylethyl group in the deprotection process.
  • 2 -Trimethylsilylethylcarbonyl chloride may be used to protect the amine nitrogen and may later be removed using sources of fluoride ion such as HF or tetraalkylammonium fluoride salts.
  • Step 4 the perhydroisoquinoline piece of formula 4 is connected to the Chloroalcohol (compound 5, Scheme I) via an epoxide intermediate (13) generated via the base-induced closure of the vicinal chlorohydrin functionality.
  • Compound 5 is produced by Kaneka Industries, Japan. Several close-open procedures in proceeding from compound 5 ⁇ compound 13 - compound 6 may be used.
  • the epoxide 13 may be isolated or it may be reacted with 4 added either subsequent to formation of 13 or 4 may be present from the beginning of the sequence.
  • the epoxide 13 can be generated using inorganic bases such as metal hydroxides, carbonates and bicarbonates in solvents such as alcohols like methanol ethanol or isopropyl alcohol, ethers such as THF and dioxane or mixtures of the two.
  • the epoxide can also be generated in a 2 -phase solvent system consisting of water and a halocarbon solvent such as dichloromethane along with the base.
  • a phase-transfer catalyst such as a tetraalkylammonium salt may be used to facilitate the process .
  • the process of opening the epoxide 13 with compound 4 is accomplished in alcohol solvents or mixtures of an alcohol and another solvent which may be an ether or a dipolar aprotic solvent such as dimethylformamide or dimethylsulfoxide .
  • the opening of the epoxide 13 with compound 4 to give compound 6 is optimally performed over a period of 2-7 hours at 50 - 60 °C.
  • the carbobenzyloxy group can be removed to give the free amine 7. This can be done using HBr in acetic acid using cosolvents such as halocarbons. It can also be performed using halides of boron such as BBr 3 and BC1 3 or alkyl substituted boron halides such as dimethylboron bromide in halocarbon solvents like chloroform and dichloromethane at temperatures ranging from 0 °C up to ambient temperature. Alternatively, the carbobenzyloxy group can be removed by hydrolysis using aqueous/alcoholic solutions of metal hydroxides like barium, sodium, lithium or potassium hydroxide at temperatures above ambient for periods of hours .
  • Step 6a is the coupling of benzoic acid derivatives of formula 8 to give 9a.
  • Q can be a leaving group.
  • Q can be any of the leaving groups discussed above for Group J.
  • the coupling can be performed using carbodiimide based methods utilizing any of the common reagents of this class including dicyclohexylcarbodiimide or related dialkylcarbodiimides, EDC (salts of l-(3- dimethylaminopropyl) -3-ethylcarbodiimide) or related water soluble reagents along with an organic amine base in polar organic solvents such as dioxane, DMF, NMP and acetonitrile in the presence of an N-hydroxyheterocyclic including N- hydroxysuccinimide or 3 -hydroxybenzotriazole .
  • polar organic solvents such as dioxane, DMF, NMP and acetonitrile
  • the coupling may be performed in most common organic solvents such as THF, diethyl ether, dioxane, methyl t-butyl ether or other ethers; acetone, cyclohexanone, methyl isobutylketone and other ketones; esters such as ethyl, methyl and isopropyl acetate; halogenated solvents such as halogenated methanes and ethanes, chlorobenzene and other halogenated benzenes; nitriles such acetonitrile and propionitrile; lower alcohols such as ethanol, isopropanol, t-butanol and related alcohols, and polar organic solvents such as dimethylformamide, dimethylsulfoxide, N-methyl-2- pyrrollidone and related amide-containing solvents.
  • organic solvents such as THF, diethyl ether, dioxane, methyl t-butyl ether or other
  • a base is frequently used and may be any of a number of inorganic bases such as metal hydroxides, bicarbonates and carbonates or organic bases such as amines like triethylamine, diethylamine, diethyl isopropylamine, DABCO or related di- or trialkylamines, as well as amidine bases like DBU and DBN.
  • inorganic bases such as metal hydroxides, bicarbonates and carbonates or organic bases such as amines like triethylamine, diethylamine, diethyl isopropylamine, DABCO or related di- or trialkylamines, as well as amidine bases like DBU and DBN.
  • Acetate removal is accomplished in step 6b with aqueous or alcoholic solutions of inorganic bases such as metal hydroxides, carbonates and bicarbonates at ambient temperatures up to 100 °C. If there is a protected functionality on the carboxamide group bonded to the perhydroisoquinoline ring system, it is best removed at this point (during or after step 6b) . The nature of this step is dependent on the exact identity of the protecting group.
  • NMR spectra were obtained on a General Electric QE-300 300MHz instrument. Chemical shifts are expressed in ⁇ values in ppm. Mass spectra were obtained on a VG ZAB-3 Spectrometer at the Scripps Research Institute, La Jolla, CA. Infra-red spectra were recorded on a Midac Corporation spectrometer. UV spectra were obtained on a Varian,Cary 3E instrument . Thin layer chromatography was carried out using silica plates available from E. Merck. Melting points were measured on a Mettler FP62 instrument and are uncorrected.
  • Benzyl chloroformate (15.8 mL, 111 mmol) was added dropwise over 30 minutes and the pH was kept between 7 and 8 by the addition of 2 N aqueous KOH. The mixture was stirred at room temperature for 18 hours. EtOAc (200 mL) was added and the organic layer was washed with 1 N aqueous HC1 (100 mL) , and brine (100 mL) . The organic layer was dried (MgS0 4 ) , filtered, and evaporated under reduced pressure to an oil. The product was purified by silica gel chromatography, eluting with 1:1 40-60 petroleum ether/EtOAc followed by 100% EtOAc.
  • Triethylamine (3.2 g, 4.3 mL, 31.2 mmol) was added to a solution of the mixture of amine 19 (4.7 g, 10.4 mmol theory from 18) and benzyl alcohol in EtOH (23 mL) at ambient temperature.
  • a solution of 3-acetoxy-2-methylbenzoyl chloride (20) (obtained according to procedures set forth in U.S. Patent Application Serial No. 08/708,411, filed September 5, 1996, which is specifically incorporated by reference herein) (2.4 g, 11.5 mmol) in THF (4 mL) was added. After 2 hours 50% aqueous NaOH (4.1 g, 2.8 mL, 52.2 mmol) was added and the mixture was heated under reflux for 1 hour.
  • HIV-1 protease gene was isolated from the viral strain IIIB (Ratner, L. et al . , Nature, 316, 227-284 (1985)).
  • the glutamine residue at position 7 was mutated to serine (S) by replacing the 33 base pairs segment between the Ndel and BstEII sites of the protease gene sequence with synthetic oligonucleotides encoding the Q7S mutation.
  • the modified gene sequence was inserted into the plasmid vector pGZ (Menge, K.L.
  • HIV-1 PR Cultures were grown in 2YT media (1.6% Trypticase Pepton, 1% Yeast extract, 0.5 % NaCl at an initial pH 7.5) containing 200 ⁇ g/L ampicillin in 100 L fermentor (Biolafitte SA) at 37 °C for 5 hours and then induced by addition of 1 ttiM IPTG ( Isopropyl - ⁇ -D- thiogalactopyranoside) . The temperature of the culture during induction was raised to 42 °C to increase accumulations of the recombinant HIV-1 protease as insoluble inclusion bodies. After 2 hours at 42°C, cells were harvested by crossflow filtration using Pellicon 0.1 ⁇ m WPP000C5 cassette #10 (Millipore) and the cell paste was stored frozen at -70°C.
  • Cell paste from 100L culture was resuspended in 300 mL of lysis buffer (50 mM Tris-Cl pH 8.0 , 25 niM NaCl , 20 M 2- mercaptoethanol) and microfluidized in Microfluidics Corporation fluidizer at 22,000 psi.
  • the crude cell lysate was clarified by centrifugation at 14,000 rpm for 20 minutes. HIV PR was found predominantly in the pellet in the form of inclusion bodies.
  • the inclusion bodies were subsequently washed multiple times in the lysis buffer containing in addition 0.1% Trition-XlOO and 1 M urea, and after each washing procedure, the inclusion bodies were pelleted by centrifugation at 5,000 rpm for 20 minutes.
  • Purified inclusion bodies were solubilized in buffer containing 50 mM Tris-Cl, pH 8.0, 25 mM NaCl, 20 mM 2- mercaptoethanol , and 8 M urea. Solution was clarified by centrifugation at 14,000 rpm and applied at room temperature to a 300 mL Fast Flow Q-Sepharose column (Pharmacia, Piscataway, NJ) equilibrated with the same buffer. Under these conditions HIV PR did not bind to the column and essentially pure enzyme was found in the flow-through fractions.
  • Proteolytic activity of purified HIV-1 protease was measured using a modified chromogenic assay developed by Richards at al . (Richards, A.D. et al . J. Biol . Chem. , 256, 773-7736 (1990)).
  • the synthetic peptide His-Lys-Ala-Arg- Val-Leu-Phe (paraN02) -Glu-Ala-Nle-Ser-NH 2 (American Peptide Company) (Nle is norleucine) was used as a substrate.
  • the assay was carried out in 0.5 M NaCl, 50 mM MES pH 5.6 , 5 mM DDT, and 2% DMSO at 37°C.
  • the CEM-SS and MT-2 human T cell lines and HIV-1 strains RF and IIIB were obtained from the AIDS Research and Reference Program, Division of AIDS, NIAID, and NIH. Cell protection assays:
  • the inhibitory effects of each agent on HIV-1 replication were measured by the MTT dye reduction method (Alley, M.C. et al . , Cancer Res. 48.: 589-601 (1988)).
  • Compounds were dissolved in DMSO at a concentration of 40 mg/ml then diluted 1:200 in culture medium (RPMI, supplemented with 10% fetal bovine serum) . From each diluted stock, 100 ⁇ l was added to a 96-well plate and serial half-log dilutions were prepared.
  • MT-2 cells and CEM-SS cells were infected with HIV-1 IIIB or HIV-1 RF at a multiplicity of infection (m.o.i.) of 0.01 and 0.03, respectively.
  • Cytotoxicity was calculated as the concentration of drug that decreased the percentage of formazan produced in uninfected, drug-treated cells to 50% of that produced in uninfected, drug-free cells.
  • the therapeutic index (TI) was calculated by dividing the cytotoxicity (TC 50 ) by the antiviral efficacy (ED 50 ) .
  • a Therapeutic index Cytotoxicity (TC50) ⁇ Antiviral activity (ED 50 ) .
  • the compounds of the present invention are useful for inhibiting HIV protease, which is an enzyme associated with viral component production and assembly.
  • An embodiment of the present invention is a method of treating HIV infection comprising administering to a host or patient, such as a primate, an effective amount of a compound of formula (9) or a pharmaceutically acceptable salt thereof.
  • Another embodiment of the present invention is a method of treating AIDS comprising administering to a host or patient an effective amount of a compound of formula (9) or a pharmaceutically acceptable salt thereof.
  • a further embodiment of the present invention is a method of inhibiting HIV protease comprising administering to an HIV infected cell or a host or patient, such as a primate, infected with HIV, an effective amount of a compound of formula (1) or a pharmaceutically acceptable salt thereof.
  • an effective amount means an amount of a compound of formula (9) or its pharmaceutically acceptable salt that is effective to inhibit the HIV protease mediated viral component production and assembly.
  • the specific dose of compound administered according to this invention to obtain therapeutic or inhibitory effects will, of course, be determined by the particular circumstances surrounding the case, including, for example, the compound administered, the route of administration, the condition being treated and the individual host or patient being treated.
  • An exemplary daily dose (administered in single or divided doses) contains a dosage level of from about 0.01 mg/kg to about 50 mg/kg of body weight of a compound of this invention.
  • Preferred daily doses generally are from about 0.05 mg/kg to about 40 mg/kg and, more preferably, from about 1.0 mg/kg to about 30 mg/kg.
  • the compounds of the invention may be administered by a variety of routes, including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular and intranasal routes.
  • the compounds of the present invention are preferably formulated prior to administration. Therefore, another embodiment of the present invention is a pharmaceutical composition or formulation comprising an effective amount of a compound of formula (9) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, such as a diluent or excipient therefor.
  • the active ingredient preferably comprises from 0.1% to 99.9% by weight of the formulation.
  • pharmaceutically acceptable it is meant that the carrier, such as the diluent or excipient, is compatible with the other ingredients of the formulation and not deleterious to the host or patient.
  • compositions of the present invention may be prepared from the compounds of the invention by known procedures using known - and readily available ingredients.
  • the active ingredient will usually be admixed with a carrier, or diluted by a carrier, or enclosed within a carrier, which may be in the form of a capsule, sachet, paper or other suitable container.
  • a carrier which may be in the form of a capsule, sachet, paper or other suitable container.
  • the carrier may be a solid, semi-solid or liquid material which acts as a vehicle, excipient or medium for the active ingredient.
  • compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments (containing, for example, up to 10% by weight of the active compound) , soft and hard gelatin capsules, suppositories, sterile injectable solutions, sterile packaged powders and the like.
  • active ingredient represents a compound of formula (9) or a pharmaceutically acceptable salt thereof.
  • Hard gelatin capsules are prepared using the following ingredients :
  • a tablet is prepared using the ingredients below:
  • the components are blended and compressed to form tablets each weighing 665 mg .
  • An aerosol solution is prepared containing the following components :
  • the active compound is mixed with ethanol and the mixture added to a portion of the propellant 22, cooled to -30°C and transferred to a filling device. The required amount is then fed to a stainless steel container and diluted with the remainder of the propellant . The valve units are then fitted to the container.
  • Tablets each containing 60 mg of active ingredient, are made as follows:
  • Microcrystalline cellulose 35 Polyvinylpyrrolidone
  • Capsules each containing 80 mg of active ingredient, are made as follows:
  • Suppositories each containing 225 mg of active ingredient, are made as follows: Active ingredient 225 mg
  • Suspensions each containing 50 mg of active ingredient per 5 ml dose, are made as follows: Active ingredient 50 mg
  • the active ingredient is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethylcellulose and syrup to form a smooth paste.
  • the benzoic acid solution, flavor and color are diluted with a portion of the water and added, with stirring. Sufficient water is then added to produce the required volume.
  • An intravenous formulation is prepared as follows: Active ingredient 100 mg Isotonic saline 1,000 mL
  • the solution of the above ingredients generally is administered intravenously to a subject at a rate of 1 ml per minute .
  • a tablet is prepared using the ingredients below:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Ces inhibiteurs de protéases du VIH, que l'on peut obtenir par synthèse chimique, sont capables d'inhiber ou de bloquer l'activité biologique de la protéase du VIH, ce qui provoque l'arrêt de la réplication du virus du VIH. Ces composés, ainsi que les compositions contenant comme principes actifs ces composés et facultativement d'autres agents antiviraux, conviennent au traitement de patients ou d'hôtes infectés par le virus du VIH, qui est connu pour provoquer le SIDA.
EP98910300A 1997-03-13 1998-03-12 Inhibiteurs de la protease du vih Withdrawn EP0970055A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US815951 1977-07-15
US81595197A 1997-03-13 1997-03-13
PCT/US1998/004735 WO1998040357A2 (fr) 1997-03-13 1998-03-12 Inhibiteurs de la protease du vih

Publications (1)

Publication Number Publication Date
EP0970055A2 true EP0970055A2 (fr) 2000-01-12

Family

ID=25219265

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98910300A Withdrawn EP0970055A2 (fr) 1997-03-13 1998-03-12 Inhibiteurs de la protease du vih

Country Status (35)

Country Link
EP (1) EP0970055A2 (fr)
JP (1) JP2001516350A (fr)
KR (1) KR100511089B1 (fr)
CN (1) CN1179948C (fr)
AP (1) AP1358A (fr)
AR (1) AR012556A1 (fr)
AU (1) AU743078B2 (fr)
BG (1) BG63540B1 (fr)
BR (1) BR9808867A (fr)
CA (1) CA2284163A1 (fr)
CO (1) CO4940496A1 (fr)
CZ (1) CZ296647B6 (fr)
EA (1) EA002378B1 (fr)
EE (1) EE04114B1 (fr)
GE (1) GEP20022764B (fr)
HR (1) HRP980112A2 (fr)
HU (1) HUP0001380A3 (fr)
IL (2) IL131870A0 (fr)
IS (1) IS5176A (fr)
MX (1) MXPA99008395A (fr)
MY (1) MY117535A (fr)
NO (1) NO315555B1 (fr)
NZ (1) NZ337706A (fr)
OA (1) OA11196A (fr)
PA (1) PA8448801A1 (fr)
PE (1) PE58799A1 (fr)
PL (1) PL192786B1 (fr)
SA (1) SA98181116B1 (fr)
SK (1) SK283636B6 (fr)
SV (1) SV1998000038A (fr)
TR (1) TR199902508T2 (fr)
TW (1) TW200517112A (fr)
UA (1) UA57772C2 (fr)
WO (1) WO1998040357A2 (fr)
ZA (1) ZA982047B (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9840357A2 *

Also Published As

Publication number Publication date
UA57772C2 (uk) 2003-07-15
NO315555B1 (no) 2003-09-22
AR012556A1 (es) 2000-11-08
EE9900416A (et) 2000-04-17
SK283636B6 (sk) 2003-11-04
CZ319199A3 (cs) 2000-06-14
NO994415D0 (no) 1999-09-10
WO1998040357A3 (fr) 1998-11-26
NZ337706A (en) 2001-04-27
PA8448801A1 (es) 2000-05-24
SV1998000038A (es) 1999-02-15
KR20000076236A (ko) 2000-12-26
TR199902508T2 (xx) 2000-02-21
BR9808867A (pt) 2000-07-11
PE58799A1 (es) 1999-07-12
CA2284163A1 (fr) 1998-09-17
SA98181116B1 (ar) 2006-10-04
EA002378B1 (ru) 2002-04-25
KR100511089B1 (ko) 2005-08-31
BG63540B1 (bg) 2002-04-30
GEP20022764B (en) 2002-08-26
EE04114B1 (et) 2003-08-15
ZA982047B (en) 1998-09-28
IL131870A0 (en) 2001-03-19
NO994415L (no) 1999-11-10
AP9901648A0 (en) 1999-09-30
CN1179948C (zh) 2004-12-15
PL192786B1 (pl) 2006-12-29
MY117535A (en) 2004-07-31
SK122299A3 (en) 2000-05-16
HUP0001380A2 (hu) 2000-09-28
IS5176A (is) 1999-09-10
PL335672A1 (en) 2000-05-08
CN1253548A (zh) 2000-05-17
TW200517112A (en) 2005-06-01
EA199900823A1 (ru) 2000-04-24
MXPA99008395A (es) 2003-08-12
IL131870A (en) 2006-04-10
JP2001516350A (ja) 2001-09-25
AU6457598A (en) 1998-09-29
CO4940496A1 (es) 2000-07-24
AP1358A (en) 2004-12-03
HRP980112A2 (en) 1998-12-31
HUP0001380A3 (en) 2001-12-28
WO1998040357A2 (fr) 1998-09-17
BG103727A (en) 2000-04-28
OA11196A (en) 2003-05-21
CZ296647B6 (cs) 2006-05-17
AU743078B2 (en) 2002-01-17

Similar Documents

Publication Publication Date Title
ES2236849T3 (es) Inhibidores de la proteasa de vih.
US5527829A (en) HIV protease inhibitors
NZ243452A (en) Inhibitors of hv protease and pharmaceutical compositions thereof
JPH06234728A (ja) Ａｉｄｓの処置のために有用なｈｉｖ−プロテアーゼ阻害剤
EP0741719A1 (fr) Intermediaire et son procede de fabrication
US6001851A (en) HIV protease inhibitors
AU743078B2 (en) HIV protease inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990910

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 19990910;LT PAYMENT 19990910;LV PAYMENT 19990910;MK PAYMENT 19990910;RO PAYMENT 19990910;SI PAYMENT 19990910

17Q First examination report despatched

Effective date: 20030523

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: JAPAN TOBACCO INC.

Owner name: AGOURON PHARMACEUTICALS, INC.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091229

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1026891

Country of ref document: HK